Search
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … [label] It is stable to many beta-lactamases.
Synonyms: N-formimidoylthienamycin, N-formimidoyl thienamycinMixtures: TIENAM 500 MG IV ENJEKTABL FLAKON, 1 ADET, VIAPENEM 500 MG/500 MG IV İNFÜZYON İÇİN KURU TOZ İÇEREN FLAKON, 1 ADETGaretosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.
Moxetumomab pasudotox
go.drugbank.com/drugs/DB12688ApprovedInvestigationalCD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.
Categories: CD22 (Clusters of Differentiation 22) inhibitorsVosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigationalAchondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. … [A242277] It results from a gain-of-function missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and in length.
Categories: Drugs for Treatment of Bone Diseases, C-type Natriuretic Peptide AnalogCholestyramine
go.drugbank.com/drugs/DB01432ApprovedInvestigationalCholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. … Cholestyramine resin is quite hydrophilic, but insoluble in water.
Categories: Compounds used in a research, industrial, or household setting, Ion Exchange ResinsProducts: ANTILIP GRANULADO EN SACHET, PHL-cholestyramine Light - 210g TinOnasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[L9194] SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness. … Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal
Categories: Genetic TherapySafflower oil
go.drugbank.com/drugs/DB09446ApprovedInvestigationalWithdrawnSafflower (_Carthamus tinctorius_ L) is a herbaceous plant in the Asteraceae family. … Safflower oil is approved for use as an indirect additive in food contact substances and is readily available as a food ingredient.
Mixtures: Liposyn II Inj 10%, Liposyn IIDiphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalWhen diphenoxylate is used alone, it is classified as a Schedule II. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Synonyms: Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate, 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl esterMixtures: LAMDOTIL®, LAMDOTIL®Sertaconazole
go.drugbank.com/drugs/DB01153ApprovedSertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.
Categories: combinations of imidazole derivatives, Heterocyclic Compounds, 1-RingProducts: Konzert Cream 2%w/w, ZALAIN® 2% CREMAPemoline
go.drugbank.com/drugs/DB01230ApprovedIllicitWithdrawnIn 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Categories: Heterocyclic Compounds, 1-Ring